Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CC 91633

Next Previous
Drug Profile

CC 91633

Alternative Names: BMS-986397; CC-91633

Latest Information Update: 19 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CRBN protein modulators; Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 06 Dec 2025 Adverse events, pharmacokinetics and efficacy data from a phase-I trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 30 Jul 2025 Celgene terminates a phase-I trial in Acute myeloid leukaemia and Myelodysplastic syndromes in USA and Spain due to overall experimental dosing regimen is not considered optimal to support further clinical development in this patient population (NCT04951778)
  • 19 Feb 2025 BMS 986397 is still in phase I trials for Acute myeloid leukaemia (Second-line therapy or greater) and Myelodysplastic syndrome (Second-line therapy or greater) in USA (PO) (NCT04951778)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top